Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer

• Published in: Clinical cancer research Vol. 26; no. 8; pp. 1965 - 1976
• Main Authors: Li, Yingming, Yang, Rendong, Henzler, Christine M., Ho, Yeung, Passow, Courtney, Auch, Benjamin, Carreira, Suzanne, Nava Rodrigues, Daniel, Bertan, Claudia, Hwang, Tae Hyun, Quigley, David A., Dang, Ha X., Morrissey, Colm, Fraser, Michael, Plymate, Stephen R., Maher, Christopher A., Feng, Felix Y., de Bono, Johann S., Dehm, Scott M.
• Format: Journal Article
• Language: English
• Published: United States 15.04.2020
• Subjects: Androgen Receptor Antagonists - pharmacology; Benzamides; Biomarkers, Tumor - genetics; Cell Line, Tumor; Drug Resistance, Neoplasm - genetics; Gene Rearrangement; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin - analogs & derivatives; Phenylthiohydantoin - pharmacology; Prospective Studies; Prostatic Neoplasms, Castration-Resistant - drug therapy; Prostatic Neoplasms, Castration-Resistant - genetics; Prostatic Neoplasms, Castration-Resistant - pathology; Receptors, Androgen - chemistry; Receptors, Androgen - genetics; Whole Genome Sequencing - methods

Prostate cancer is the second leading cause of male cancer deaths. Castration-resistant prostate cancer (CRPC) is a lethal stage of the disease that emerges when endocrine therapies are no longer effective at suppressing activity of the androgen receptor (AR) transcription factor. The purpose of thi...